AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred. The full study is available here.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

TTG Imaging Solutions

OCTOBER 20, 2021

The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Radiation Oncology 52

Radiation Oncology Imaging Radiopharmaceuticals Radiation 52

AuntMinnie

JUNE 14, 2024

Extravasations have never been required to be reported, NRC's senior health physicist Cindy Flannery said June 11 during a regulatory session at the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) recent meeting in Toronto. That might do away with diagnostic concerns, Flannery noted.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Medical 52

Future Teleradiology

NOVEMBER 27, 2023

Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies.

Hospital 103

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 103

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics.

Healthcare 95

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 95

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 86

Nuclear Medicine Radiation Oncology Nursing Radiation 86

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Chief Executive Officer of Blue Earth Diagnostics.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

JULY 25, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 89

Radiopharmaceuticals Imaging Pharmaceutical Disease 89

Imaging Technology

JULY 11, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 70

Radiopharmaceuticals Imaging Pharmaceutical Disease 70

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 92

Diagnostic Radiopharmaceuticals Imaging Radiation 92

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 82

Medical Radiopharmaceuticals Pharmaceutical Radiation 82

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.

Clinic 82

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 82

Future Teleradiology

NOVEMBER 21, 2023

Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclear medicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology 52